85. Idiopathic interstitial pneumonia Clinical trials / Disease details

Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05052229 (ClinicalTrials.gov)	April 21, 2022	2/9/2021	Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).	Pulmonary Gas Exchange and Neuro-sensory Abnormalities in Patients With Idiopathic Pulmonary Fibrosis and Mild Mechanical Restriction. Implications for Dyspnea and Exercise Intolerance	Idiopathic Pulmonary Fibrosis	Drug: Nitric Oxide;Drug: Medical air	Queen's University	Boehringer Ingelheim	Recruiting	40 Years	N/A	All	40	Early Phase 1	Canada
2	NCT03688334 (ClinicalTrials.gov)	June 1, 2018	20/9/2018	Acute Effects of Oxygen Supplementation Among IPF Patients	Acute Effects of Oxygen Supplementation During Exercise Among Patients With Idiopathic Pulmonary Fibrosis Without Resting Hypoxemia	Idiopathic Pulmonary Fibrosis	Drug: Oxygen 40 %;Drug: Medical air (sham O2)	George Papanicolaou Hospital	NULL	Unknown status	18 Years	80 Years	All	15	N/A	Greece
3	JPRN-UMIN000015508	2015/01/01	24/10/2014	A prospective randomized, multicenter trial evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis.	A prospective randomized, multicenter trial evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. - Combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis.	Idiopathic pulmonary fibrosis	Using Micro Air nebulizers and vibration mesh technology (NE-U07, Omron, Tokyo, Japan), patients receiving NAC combined with pirfenidone were treated twice daily with 352.4 mg of inhaled NAC, which was diluted with saline to a total volume of 6 mL for 48 weeks. Pirfenidone 1200-1800mg (control group)	Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.	NULL	Complete: follow-up complete	40years-old	Not applicable	Male and Female	150	Not selected	Japan
4	JPRN-UMIN000005098	2011/02/01	18/02/2011	A randomized trial of ambulatory oxygen in patients with idiopathic pulmonary fibrosis and desaturation but without resting hypoxemia	A randomized trial of ambulatory oxygen in patients with idiopathic pulmonary fibrosis and desaturation but without resting hypoxemia - ambulatory oxygen in patients with IPF and desaturation but without resting hypoxemia	idiopathic pulmonary fibrosis	ambulatory oxygen ambulatory air	Department of Respiratory Medicine and Allergology, Kinki University School of Medicine	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	20	Not selected	Japan
5	JPRN-UMIN000016045	2009/10/03	26/12/2014	A case-control study evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis.	A case-control study evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. - Combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis.	Idiopathic pulmonary fibrosis	Using Micro Air nebulizers and vibration mesh technology (NE-U07, Omron, Tokyo, Japan), patients receiving NAC combined with pirfenidone were treated twice daily with 352.4 mg of inhaled NAC, which was diluted with saline to a total volume of 6 mL for 48 weeks. Pirfenidone 1200-1800mg (control group)	Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo	,NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	20	Not selected	Japan